25 results about "Cardiac sudden death" patented technology

The invention relates to a method for the magnetocardiographic characterization of at least a portion of a heartbeat cycle of a heart of a subject. Magnetocardiographic parameter obtained by the method can, for example, be used for the prediction of a risk for sudden cardiac death (SCD) in a subject.

The invention relates to a method for the magnetocardiographic characterization of at least a portion of a heartbeat cycle of a heart of a subject. Magnetocardiographic parameter obtained by the method can, for example, be used for the prediction of a risk for sudden cardiac death, SCD, in a subject.

The present application belongs to the field of intelligent medical treatment and health monitoring technology, and specifically relates to a heart-source sudden death risk monitoring and early warning system and method based on multi-source signal collaborative analysis. The method aims to solve the technical problem of signal quality degradation caused by motion artifact interference in existing wearable electrocardio monitoring. It includes: synchronously collecting electrocardio signals and three-axis acceleration signals through a wearable device, performing adaptive motion artifact filtering based on acceleration reference, power frequency notch filtering and baseline drift correction; performing QRS wave detection and feature extraction on the preprocessed waveform, combining with the motion intensity index to mark the candidate risk event segment; transmitting the structured event data packet to a mobile terminal, outputting the risk arrhythmia confidence degree by using a lightweight time sequence neural network model, and performing comprehensive risk assessment by fusing the event duration and frequency, the user real-time activity state and the individualized historical baseline; and performing differentiated response strategies according to the risk level.

The invention discloses a method for constructing a cardiac resuscitation visualization process. The method comprises the following steps: collecting multi-source data; constructing an arrhythmia automatic identification model based on deep learning; judging the vital sign state of the patient; analyzing by using a machine learning algorithm to evaluate the severity of the illness state; through the Internet of Things technology, real-time positioning and state monitoring are carried out on first-aid resources in a hospital; an optimal first-aid resource allocation scheme is automatically calculated; analyzing the relationship between each factor and the cured patient to obtain key factors and potential problem points of the treatment success rate; a personalized cardiac resuscitation advanced life support process is generated based on an artificial intelligence algorithm and is visually displayed, and first-aid operation steps and time node guidance are provided for first-aid personnel. According to the method, the whole process of cardiac resuscitation is realized by fully utilizing an artificial intelligence technology, and intelligence and visualization of each link are realized, so that the treatment timeliness and success rate of sudden cardiac death patients are remarkably improved.

This invention discloses a method for predicting sudden cardiac death based on forensic autopsy data using machine learning and its forensic applications, belonging to the fields of machine learning, statistics, and forensic identification. This invention provides a method for screening independent predictors of forensic diagnosis of sudden cardiac death using LASSO regression and logistic regression. Using 10-fold cross-validation, the method selects the minimum lambda(λ) to identify 14 risk factors. Logistic regression ultimately identifies 9 independent predictors, including age, heart weight, left ventricular wall thickness, right ventricular wall thickness, interventricular septum thickness, aortic valve circumference, mitral valve circumference, liver weight, and left kidney weight. A nomogram and a web-based calculator are constructed for predicting sudden cardiac death in forensic practice, thereby determining sudden cardiac death using objective indicators. This method has not been reported worldwide.

The application provides a method and device for generating a cardiac limit survival view, comprising: constructing a cardiac simulation model based on static clinical data; inputting basic physiological state data into a generative adversarial network to obtain a stress condition matrix; simulating based on the stress condition matrix and the cardiac simulation model to generate a simulation result; determining a limit instability evaluation result based on the simulation result, if the limit instability evaluation result indicates reaching a limit instability state, recording the current stress condition matrix as a critical condition matrix, and generating a new stress condition matrix based on the critical condition matrix; if the limit instability evaluation result indicates not reaching the limit instability state, updating the generative adversarial network based on the simulation result and the stress condition matrix; after meeting a preset iteration termination condition, generating a cardiac limit survival view of a target object based on multiple critical condition matrices. The application changes the traditional passive recording of abnormal events into active exploration, effectively reducing the misdiagnosis rate of malignant events such as sudden cardiac death.

The invention relates to the field of medicine, and provides a sudden cardiac death diagnosis model and a construction method thereof, and the method comprises the steps: collecting data samples, and constructing a training set based on the data samples, the training set comprises diagnosis features, and the diagnosis features represent that the data samples in the training set are sudden cardiac death; performing data interpolation and variable screening on the diagnosis features in the training set; a logistic regression model is constructed based on the training set, independent variables of the logistic regression model are diagnosis features, and dependent variables of the logistic regression model are diagnosis results of samples corresponding to the diagnosis features; and constructing a diagnosis calculator based on the logistic regression model, wherein the diagnosis calculator inputs the received characteristic values into the logistic regression model to diagnose sudden cardiac death. The sudden cardiac death diagnosis method and device are used for overcoming the defect that a diagnosis result is not accurate enough mainly depending on subjective experience of a forensic when sudden cardiac death diagnosis is carried out at present, and the sudden cardiac death diagnosis method and device can carry out accurate diagnosis on sudden cardiac death.

The present invention relates to the field of ultrasounds and imagining of the coronary blood flow of the heart. Patients with coronary microvascular dysfunction (CMD) have poor prognostic with significantly higher rates of cardiovascular events, including hospitalization for heart failure, sudden cardiac death, and myocardial infarction (MI). Despite the urgent clinical need, there are no non-ionizing and non-invasive techniques available in clinic to directly visualize the coronary microvasculature and assess the local coronary microvascular system. Flow imaging remains a difficult task to perform in the heart because of the fast movements of this organ. In order to overcome the limitations of actual imaging methods for the coronary blood flow, the inventors proposed an ultrasound ultrafast imaging method that automatically detect the time periods in which the myocardium velocity is low and estimate the coronary flow velocity and the tissue velocity from the same data acquisition.

The invention belongs to the technical field of biological medicines, and particularly discloses application of colchicine in preparation of a medicine for treating hypertrophic cardiomyopathy. Researches show that after colchicine is used for treatment, pathological changes such as cardiac fibrosis of hypertrophic cardiomyopathy are relieved. Further experimental results show that after colchicine treatment, the proportion of pro-inflammatory macrophages in the cardiac hypertrophy tissue is reduced, the IL-6 level is reduced, and it is prompted that the anti-inflammatory ability of colchicine can improve the microenvironment of the cardiac hypertrophy tissue, so that fibrosis is relieved, and the cardiac function is improved. The invention proves the clinical transformation potential of colchicine in the treatment of cardiac hypertrophy patients. If the medicine is applied clinically in the future, the risk of sudden cardiac death is expected to be reduced by relieving cardiac fibrosis, and a new treatment choice is provided for improving the prognosis of a hypertrophic cardiomyopathy patient.

This invention provides a safer drug and its application, and a safer drug combination and its application without sudden cardiac death toxicity. The safer drug provided by this invention is a combination preparation containing a serotonin receptor antagonist and diltiazem, which effectively avoids the possibility of ventricular depolarization and repolarization disorders caused by the serotonin receptor antagonist ondansetron, thereby preventing corresponding arrhythmias and sudden cardiac death. This application also provides the application of diltiazem in the preparation of drugs that improve cardiac electrical activity and corresponding treatment methods.

The invention provides a probe composition for detecting hereditary sudden cardiac death and application of the probe composition. The probe composition for detecting the hereditary sudden cardiac death comprises 20388 probes which are consistent with or complementary to the sequences of corresponding sites on a chromosome of a human reference genome hg19. The probe composition for detecting the hereditary sudden cardiac death can be used for detecting the coding regions of 99 genes and the non-coding regions of 29 genes related to the hereditary sudden cardiac death at one time, so that the detection of various mutation types of the hereditary sudden cardiac death, such as cardiac ion channel disease, cardiomyopathy and hereditary aorta disease, is realized; the detection content coverage is wide, and the detection efficiency is high, so that the occurrence and genetic risk of the hereditary sudden cardiac death can be comprehensively evaluated, and the method has important significance on early prevention, early intervention and auxiliary diagnosis.

The invention provides application of circulating protein FGF23 in predicting sudden cardiac death risk of chronic kidney disease patients and model construction, and belongs to the technical field of medicines. The biomarkers comprise NTproBNP (N-terminal B-type natriuretic peptide), DTNB (heteronectin beta), ANGPT2 (angiopoietin 2), FGF23 (fibroblast growth factor 23) and SEPTIN8 (cytokinin 8), wherein the circulating protein FGF23 has the best prediction effect after the risk ratio and AUC evaluation are combined. The FGF23 marker is provided for early prediction of sudden cardiac death after chronic kidney disease, and a technical means is provided for prognosis evaluation of chronic kidney disease treatment.

The present application relates to the technical field of disease risk prediction, and particularly relates to a ten-year risk prediction method, system and device for sudden cardiac death, the method comprising: obtaining 48-hour electrocardiogram data of an individual sample and a risk classification evaluation result based on a China-PAR risk assessment model; splitting and combining the electrocardiogram data to obtain a preset multi-dimensional waveform graph; constructing a convolutional neural network model, taking the waveform graph as input and the corresponding risk classification evaluation result as output to train the model and obtain a sudden cardiac death risk prediction model; inputting the processed waveform graph of 48-hour electrocardiogram data of a subject into the prediction model, and outputting the result as a ten-year sudden cardiac death risk prediction level result. The present application can create a non-linear, high-precision, and iterative sudden cardiac death risk deep learning model for the general population and doctors, improve the detection rate of sudden cardiac death, and reduce the recurrence rate and mortality.

The invention relates to an SERS (Surface Enhanced Raman Scattering) component for capturing markers in blood fluid by utilizing antigen-antibody reaction and a preparation method of the SERS component. The preparation method comprises the following steps: preparing a PDA (Personal Digital Assistant) chip aiming at a target marker, preparing a micro-fluidic chip and assembling the SERS assembly. The obtained SERS assembly can be applied to sudden cardiac death early screening. The manufacturing cost and the process difficulty of the micro-fluidic chip can be reduced, and the micro-fluidic chip can be used in cooperation with a portable Raman spectrometer for detection and can be thrown for use.

The application provides a probe composition for detecting genetic cardiogenic sudden death and application thereof. The probe composition for detecting genetic cardiogenic sudden death comprises 20388 probes which are identical or complementary to the sequences between the corresponding sites on the chromosomes of the human reference genome hg19. The probe composition for detecting genetic cardiogenic sudden death can detect the coding regions of 99 genes related to genetic cardiogenic sudden death and the non-coding regions of 29 genes at one time, realize the detection of various mutation types of genetic cardiogenic sudden death such as cardiac ion channel disease, cardiomyopathy, genetic aortic disease and the like, the detection content has wide coverage, the detection efficiency is high, and therefore the occurrence and genetic risk of genetic cardiogenic sudden death can be comprehensively evaluated, which has important significance for early prevention, early intervention and auxiliary diagnosis.

The application relates to the medical field and provides a diagnosis model for cardiogenic sudden death and a construction method thereof, wherein the method comprises the following steps: collecting data samples, and constructing a training set based on the data samples, wherein the training set comprises diagnosis features, and the diagnosis features represent the data samples in the training set as cardiogenic sudden death; data interpolation and variable screening are performed on the diagnosis features in the training set; a logistic regression model is constructed based on the training set, wherein independent variables of the logistic regression model are the diagnosis features, and dependent variables of the logistic regression model are diagnosis results of samples corresponding to the diagnosis features; and a diagnosis calculator is constructed based on the logistic regression model, wherein the diagnosis calculator inputs received feature values into the logistic regression model to diagnose cardiogenic sudden death. The application can accurately diagnose cardiogenic sudden death, and solves the problem that the diagnosis result of cardiogenic sudden death is mainly dependent on the subjective experience of a forensic doctor, and the result is not accurate enough.

The invention provides a safer medicine and application thereof, and provides a safer medicine composition without sudden cardiac death toxicity and application thereof. The safer medicine provided by the invention is a compound preparation containing the 5-hydroxytryptamine receptor antagonist and diltiazem, and can effectively avoid the possibility of corresponding arrhythmia and sudden cardiac death caused by ventricular depolarization and repolarization disorder caused by the 5-hydroxytryptamine receptor antagonist ondansetron. The invention also provides application of diltiazem in preparation of medicines for improving cardiac electrical activity and a corresponding treatment method.

The invention relates to a jettisonable kit cooperating with a portable Raman spectrometer for detection. The jettisonable kit comprises a kit body, and the top surface of the kit body is provided with a group of SERS scanning holes, a pull rod hole and a sample adding port; a pull rod is arranged in the pull rod hole; a sample tube is arranged in the box body; a group of capturing devices are arranged in the box body, and each capturing device is in transmission connection with the pull rod through a transmission mechanism; each capturing device is provided with a vertically arranged capillary tube bundle, and the tail end of each capillary tube bundle extends into the sample tube; a group of SERS (Surface Enhanced Raman Scattering) detection substrates adopting micro-fluidic chips are arranged above the capturing device in the box body; each SERS detection substrate is positioned right below the corresponding SERS scanning hole; and a base protection device for locking the pull rod is arranged in the box body. According to the kit disclosed by the invention, the SERS technology and the microfluidic technology are utilized, and a plurality of SERS detection substrates can be used at the same time, so that a plurality of indexes of the same sample can be rapidly detected, and the kit can be applied to rapid detection of sudden cardiac death risk assessment.

The present invention relates to the field of ultrasound and imaging of coronary blood flow in the heart. Patients with coronary microvascular dysfunction (CMD) have a poor prognosis and a significantly higher incidence of cardiovascular events, including heart failure, sudden cardiac death, and myocardial infarction (MI) hospitalization. Despite the urgent clinical need, there are no non-ionizing and non-invasive techniques available clinically for directly visualizing the coronary microvasculature and assessing the local coronary microvasculature. Blood flow imaging remains a difficult task in the heart due to the rapid motion of this organ. To overcome the limitations of practical imaging methods for coronary blood flow, the inventors have proposed an ultrasound ultrafast imaging method that automatically detects time periods of low myocardial velocity and estimates coronary blood flow velocity and tissue velocity from the same data acquisition.

The invention relates to the technical field of disease risk assessment, in particular to a pet cat sudden cardiac death risk assessment method, which comprises the following steps: collecting pet cat physical examination case information; constructing a sudden cardiac death risk assessment model of the pet cat according to the collected physical examination case information of the pet cat, and screening out characteristic indexes related to sudden cardiac death of the pet cat; and obtaining detection report data of a to-be-evaluated pet cat, and inputting the detection report data into the sudden cardiac death risk evaluation model of the pet cat to obtain a sudden cardiac death risk evaluation result of the pet cat. Scientific support can be provided for early diagnosis and identification of heart diseases of pet cats, and the risk level of potential sudden cardiac death can be predicted, so that timely and effective prevention measures can be taken, the life quality of pets can be improved, and scientization and standardization of pet medical services can be promoted.

Provided are a safer drug and the use thereof. Provided are a pharmaceutical composition which is safer and which does not have toxicity leading to sudden cardiac death, and the use thereof. The provided safer drug is a compound formulation containing a 5-hydroxytryptamine receptor antagonist and diltiazem, and can effectively avoid the possibility of cardiac arrhythmia and sudden cardiac death due to ventricular depolarization and repolarization disorders caused by the 5-hydroxytryptamine receptor antagonist ondansetron. Further provided are the use of diltiazem in preparing a drug for improving electrical activity of the heart and a corresponding therapeutic method.

The invention provides a novel anti-cancer drug for improving toxic and side effects of the heart and application thereof, the anti-cancer drug is a compound preparation containing a kinase inhibitor and a calcium ion antagonist, and the anti-cancer drug can effectively reduce ventricular depolarization and repolarization disorder caused by the kinase inhibitor nilotinib and the like. And then the possibility of triggering arrhythmia and / or sudden cardiac death. The invention also provides an application of the calcium channel blocker diltiazem in preparation of a medicine for improving cardiac electrical activity and a corresponding treatment method.

The invention provides a sudden cardiac death early warning method based on wearable device signals and gene markers, which comprises the following steps: extracting user history medical records and whole genome SNP sites by using natural language processing and a bioinformatics algorithm, and screening to obtain key gene markers; wearable equipment is adopted for multidimensional physiological signals and clustering division of state intervals, genes and physiological parameters are combined, and a gene-physiological isomerism coupling map is established through cross-modal mutual information and causal analysis; performing edge weight updating and sparse screening by using a dynamic graph learning and minimum spanning tree method with L1 regularization, and extracting a core interaction path; based on symbolic regression and Bayesian optimization technologies, constructing a dynamic risk assessment equation, and performing individual risk grading and interaction chain attribution on real-time physiological data; finally, a multi-level visual report is generated, visual risk judgment and decision support are provided for clinicians, and the accuracy, timeliness and medical interpretation of sudden cardiac death risk assessment are improved.

The invention provides a novel safe antiemetic drug and application thereof. The novel safe antiemetic drug provided by the invention is a compound preparation containing the 5-hydroxytryptamine receptor antagonist and the potassium ion channel opener, can effectively avoid QT interval prolonging caused by the 5-hydroxytryptamine receptor antagonist ondansetron, and reduces the possibility of corresponding arrhythmia, tachycardia and sudden cardiac death. The invention also provides an application of the potassium channel opener in preparation of a medicine for reducing QT interval extension and a corresponding treatment method.